AMD Clinical Trial
Official title:
Understanding Imaging Biomarkers That Predict the Progression of Age-Related Macular Degeneration on Multi-modal Novel Retinal Technologies
To study qualitatively and quantitatively the Imaging Biomarkers (IBs) on Multi-modal Imaging with Novel technologies (MINT), in order to understand their role in prediction of the Age-related Macular Degeneration (AMD) progression in eyes with and without treatment. The understanding of IBs will allow early detection of AMD, prediction of its evolution, and guidance for the best options for stratified/individualized treatment of AMD.
The qualitative studies will explore use of OCT Angiography (OCTA), Swept Source OCT
(SS-OCT), Ultra-Wide Field Fluorescein Angiography (UWF-FA), Adaptive Optic Scanning Laser
Ophthalmoscopy (AO-SLO), Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO), Retro Mode
Imaging (RMI) and other novel technologies for the retinal diagnosis. Morphologic qualitative
IBs described in the literature like macular neovascularization pattern, retinal tubulations,
choriocapillary preservation, retinal pigment epithelium atrophy, drusen patterns, etc as
well as other IBPAMD original IBs classified in morphopathogenic categories like IBs
related-to-MNV, IBs related-to-atrophy, IBs related-to macular chorio-retinal architecture,
etc are analyzed in granular fashion by multi-modal imaging approach before and after
different treatments for AMD.
The quantitative IBs assessment will be done in dual mode - classic and original to the
IBPAMD trial. The lesions are quantitatively assessed on one hand, by using the classic
measurements of the greatest diameter, total lesions area, vessels density, fractal
dimension, etc, based on the classic concept of measurements expressed in absolute values
(mm, mm2 or pixels). The same lesions are quantitatively assessed by using the original
IBPAMD algorithm and software (SITE-app) that introduce a new concept in the quantification
of the retinal lesions, the assessment of differences reported to the baseline.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
| Recruiting |
NCT03893474 -
Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners
|
N/A | |
| Completed |
NCT00971464 -
Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation
|
Phase 2 | |
| Terminated |
NCT00332657 -
Anecortave Acetate Risk Reduction Trial (AART)
|
Phase 3 | |
| Recruiting |
NCT04796545 -
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
|
N/A | |
| Completed |
NCT01766596 -
Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort)
|
N/A | |
| Completed |
NCT03322930 -
Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)
|
||
| Completed |
NCT01778491 -
AMD Phenotype and Genotype Study
|
||
| Completed |
NCT01016873 -
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
|
Phase 2 | |
| Active, not recruiting |
NCT03845582 -
Phase 3 Study of ALK-001 in Geographic Atrophy
|
Phase 3 | |
| Completed |
NCT03372746 -
Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration
|
||
| Completed |
NCT03367767 -
Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On
|
||
| Terminated |
NCT00333216 -
Anecortave Acetate Risk-Reduction Trial (AART)
|
Phase 3 | |
| Completed |
NCT01570790 -
Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
| Completed |
NCT00346866 -
Anecortave Acetate Versus Placebo in AMD Patients Following PDT
|
Phase 2 | |
| Withdrawn |
NCT00726466 -
Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration
|
Phase 1 | |
| Completed |
NCT00306488 -
OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration
|
Phase 2 | |
| Terminated |
NCT02348359 -
X-82 to Treat Age-related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT01632527 -
Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01339949 -
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
|
N/A |